CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
10 citations
,
September 2021 in “The FASEB Journal” ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
53 citations
,
May 1996 in “The Journal of Clinical Endocrinology & Metabolism” Different mutations in the 5 alpha-reductase-2 gene were found in affected individuals in the Dominican Republic, suggesting no common ancestry.
September 2023 in “Journal of the American Academy of Dermatology”
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
June 2023 in “British Journal of Dermatology” Coinheritance of BRCA2 and CYLD genes may lead to new treatment options for certain cancers.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
3 citations
,
February 2023 in “Journal of Investigative Dermatology” Ch55 may help reduce skin scarring and fibrosis.
86 citations
,
November 2015 in “Journal of Gastroenterology” The NUDT15 R139C variant causes thiopurine-induced leukocytopenia through a different mechanism than previously thought in Japanese patients with inflammatory bowel disease.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
32 citations
,
May 2022 in “Frontiers in Pharmacology” The method effectively predicts new drug uses, including potential COVID-19 treatments.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
October 2014 in “Cancer Research” A new topical treatment may prevent hair loss from cancer therapy by adjusting cell death processes in hair follicles.
50 citations
,
December 2005 in “European Journal of Immunology” RXRα is crucial for proper immune response and links diet to immune function.
April 2025 in “Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )” Cuscuta reflexa extract may help treat benign prostatic hyperplasia by reducing inflammation and oxidative stress.
October 2023 in “Journal of cystic fibrosis”
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
15 citations
,
June 2014 in “Behavioural Brain Research” Neurosteroids may help metyrapone reduce cocaine addiction.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
October 2016 in “Letters in Drug Design & Discovery”
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
43 citations
,
May 1999 in “Journal of Biological Chemistry” Agouti protein affects melanocortin receptors through competitive antagonism and receptor down-regulation.
January 2025 in “Molecules” Non-viral delivery systems and stimuli-responsive nanoformulations can improve CRISPR-Cas9 gene therapy.
1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.